Literature DB >> 21641676

Reappraisal of the provisional entity primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma: a series of 10 adult and pediatric patients and review of the literature.

Christian L Baum1, Brian K Link2, Vishala T Neppalli3, Brian L Swick4, Vincent Liu5.   

Abstract

BACKGROUND: Primary cutaneous CD4(+) small/medium-sized pleomorphic T-cell lymphoma (PCSM-TCL) was defined as a provisional entity in the 2005 World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas. A limited number of reports describe a generally indolent but heterogeneous condition.
OBJECTIVE: We reviewed the concept of PCSM-TCL when applied to our experience and to the published literature.
METHODS: We conducted a retrospective chart review and a PubMed search to identify all reported cases of PCSM-TCL from 2005 to 2010.
RESULTS: Ten patients, including 4 of the youngest described, were identified in our institution, and their clinical and pathologic features were analyzed. All had a benign clinical course. Ten reports of patients with PCSM-TCL were reviewed and commonalities were found within an otherwise variable spectrum of clinical presentation, pathology, and biologic behavior. LIMITATIONS: This study was retrospective, follow-up was short term in some cases, and data were limited in a number of published reports.
CONCLUSIONS: Our experience of 10 cases that met the diagnostic criteria of the provisional entity PCSM-TCL highlights its occurrence in children and further supports characterization of this condition as a clonal T-cell lymphoproliferative disorder with indolent behavior.
Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21641676     DOI: 10.1016/j.jaad.2010.07.028

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

Review 1.  Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides.

Authors:  Meenal Kheterpal; Neha Mehta-Shah; Pooja Virmani; Patricia L Myskowski; Alison Moskowitz; Steven M Horwitz
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

2.  Long-term follow-up and management of small and medium-sized CD4+ T cell lymphoma and CD8+ lymphoid proliferations of acral sites: a multicenter experience.

Authors:  Pooja Virmani; Sarah Jawed; Patricia L Myskowski; Steven Horwitz; Anna Skripnik Lucas; Alison Moskowitz; Melissa Pulitzer; Jasmine Zain; Steven T Rosen; Christiane Querfeld
Journal:  Int J Dermatol       Date:  2016-11       Impact factor: 2.736

3.  Follicular variant of peripheral T cell lymphoma with mediastinal involvement in a child: a case report.

Authors:  Audrey Delas; Philippe Gaulard; Geneviève Plat; Pierre Brousset; Camille Laurent
Journal:  Virchows Arch       Date:  2015-01-22       Impact factor: 4.064

Review 4.  Recent advances in cutaneous lymphoma-implications for current and future classifications.

Authors:  J R Goodlad; L Cerroni; S H Swerdlow
Journal:  Virchows Arch       Date:  2022-10-24       Impact factor: 4.535

5.  Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma.

Authors:  Han Ma; Shu Qiu; Rongbiao Lu; Peiying Feng; Chun Lu
Journal:  An Bras Dermatol       Date:  2016 May-Jun       Impact factor: 1.896

Review 6.  New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.

Authors:  Kazuyasu Fujii
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

7.  Case for diagnosis. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.

Authors:  Flávia de Oliveira Valentim; Cristiano Claudino Oliveira; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2019 Jan-Feb       Impact factor: 1.896

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.